LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
모멘텀 입력값 (비교 가능한 운용사): 보유자 폭 0.0% · 주식 흐름 -3.2% · 순 신규 포지션 0.0% — 산식
모든 소유권 수치: 추적 대상 13F 운용사 한정, 보통주 포지션, 보고 기간 Q1 2025
| 분기 | 보유자 | Δ | 주식 수 | 보고 가치 | 신규 | 청산 |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | 운용사 | 주식 수 | Δ 주식 수 | 가치 | 비중 | 보유 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (패시브) | 34.44M | +0.4% | $28.44B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 19.13M | -8.3% | $15.80B | 2.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 19.13M | -8.3% | $15.80B | 2.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (패시브) | 18.53M | +6.6% | $15.25B | 1.2% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (패시브) | 18.53M | +6.6% | $15.25B | 1.2% | ▲ Add | 4 | SEC ↗ |
| 6 | Capital World Investors ✦ | 18.38M | -6.0% | $15.18B | 2.5% | ▼ Trim | 4 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 14.78M | -11.8% | $12.21B | 10.1% | ▼ Trim | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Norges Bank ✦ (패시브) | 11.00M | +1.0% | $9.08B | 1.3% | ▲ Add | 4 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 5.44M | +3.9% | $4.49B | 1.9% | ▲ Add | 4 | SEC ↗ |
| 19 | Tiger Global Management ✦ | 1.33M | +1.9% | $1.10B | 4.1% | ▲ Add | 4 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 741.72K | +1.2% | $612.60M | 1.1% | ▲ Add | 4 | SEC ↗ |
| 21 | Millennium Management ✦ | 681.01K | -15.0% | $562.46M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 573.33K | -53.8% | $473.52M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 573.33K | -53.8% | $473.52M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 31 | Lone Pine Capital ✦ | 551.83K | -29.5% | $455.76M | 4.0% | ▼ Trim | 2 | SEC ↗ |
| 32 | Citadel Advisors ✦ | 477.78K | -21.8% | $394.60M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 33 | Citadel Advisors ✦ | 477.78K | -21.8% | $394.60M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 34 | Marshall Wace ✦ | 419.50K | +7.9% | $346.47M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 35 | Marshall Wace ✦ | 419.50K | +7.9% | $346.47M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 36 | Marshall Wace ✦ | 419.50K | +7.9% | $346.47M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 37 | Marshall Wace ✦ | 419.50K | +7.9% | $346.47M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 38 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 39 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 40 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 41 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 42 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 43 | Renaissance Technologies ✦ | 96.31K | +78.0% | $79.55M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 44 | Duquesne Family Office ✦ | 94.83K | +52.5% | $78.32M | 2.6% | ▲ Add | 2 | SEC ↗ |
| 45 | Point72 Asset Management ✦ | 54.77K | 신규 | $45.24M | 0.1% | New | 1 | SEC ↗ |
| 46 | Dodge & Cox ✦ | 45.09K | +0.7% | $37.24M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 47 | Arrowstreet Capital ✦ | 41.41K | +178.9% | $34.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 48 | GAMCO Investors ✦ | 30.07K | -10.3% | $24.84M | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 49 | Two Sigma Investments ✦ | 15.73K | -95.1% | $12.99M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 50 | Gotham Asset Management ✦ | 7.55K | +30.6% | $6.23M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 51 | Bridgewater Associates ✦ | 2.75K | -96.7% | $2.27M | 0.0% | ▼ Trim | 4 | SEC ↗ |
"해당 운용사 비중" = 해당 운용사의 신고된 13F 주식 가치 대비 포지션 비중 — 확신도 지표. ✦ = 선별 운용사.
신규 매수자
| Point72 Asset Management | $45.24M | 0.1% |
청산됨
| Soros Fund Management | $25.97M | 이었음 0.7% |
전체 시장 맥락: 전체 13F 공시 기관 기준 (SEC 구조화 데이터, Q1 2026): 4,323 보유 기관, 762.84M 주식, $674.93B 신고 기준. 이는 위의 추적 유니버스 수치와 다른 이전 기간으로, 두 수치는 절대 혼용되지 않습니다.
이 증권의 추적 보유자들이 가장 많이 함께 보유하는 종목 — 기본적 관계가 아닌 공동 보유 건수 기준.
공개시장 매수 (P)
당사 커버리지 기간 내 공개시장 내부자 매수가 없습니다.
공개시장 매도 (S)
Officer · 6.50K 주(sh) · $7.64M
Officer · 2.00K 주(sh) · $2.37M
Officer · 5.00K 주(sh) · $5.95M
부여, 행사 및 세금 원천징수는 매수 또는 매도로 집계하지 않습니다. 방법론
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters